【结 构 式】 |
【药物名称】BMS-248360 【化学名称】4'-(2-Butyl-4-oxo-1,3-diazaspiro[4.4]-1-nonen-3-ylmethyl)-N-(3,4-dimethylisoxazol-5-yl)-2'-(3,3-dimethyl-2-oxopyrrolidin-1-ylmethyl)biphenyl-2-sulfonamide 【CA登记号】254737-87-6 【 分 子 式 】C36H45N5O5S 【 分 子 量 】659.85455 |
【开发单位】Bristol-Myers Squibb (Originator) 【药理作用】CARDIOVASCULAR DRUGS, Hypertension, Treatment of, Angiotensin AT1 Antagonists, Endothelin ETA Receptor Antagonists |
合成路线1
The intermediate biphenyl aldehyde (XI) is prepared by two related methods. 4-Bromo-3-methylbenzonitrile (I) is oxidized to aldehyde (II) via radical bromination with N-bromosuccinimide/benzoyl peroxide, followed by treatment with trimethylamine N-oxide. Suzuki coupling of aryl bromide (II) with the pinacol boronate (III) affords biphenyl (IV). After protection of the aldehyde moiety of (IV) as the corresponding ethylene ketal (V), its cyano group is reduced to aldehyde (VI) employing DIBAL in THF. Subsequent reduction of (VI) with NaBH4 leads to alcohol (VII), which is further converted into the benzyl bromide (VIII) by means of CBr4/PPh3. Bromide (VIII) is condensed with the spiro imidazolone (IX) in the presence of NaH, to produce (X). Then acidic hydrolysis of the ethylene ketal and SEM groups of (X) gives rise to the intermediate aldehyde (XI)
【1】 Macor, J.E.; Murugesan, N.; Gu, Z.; Tellew, J.E. (Bristol-Myers Squibb Co.); Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists. EP 1094816; JP 2002519380; US 2002143024; WO 0001389 . |
【2】 Macor, J.E.; Murugesan, N.; Gu, Z.; Tellew, J.E. (Bristol-Myers Squibb Co.); Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists. EP 1237888; WO 0144239 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 60902 | 4-bromo-3-methylbenzonitrile | C8H6BrN | 详情 | 详情 | |
(II) | 60903 | 4-bromo-3-formylbenzonitrile | C8H4BrNO | 详情 | 详情 | |
(III) | 60904 | N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide | C21H31BN2O7S | 详情 | 详情 | |
(IV) | 60905 | 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C23H23N3O6S | 详情 | 详情 | |
(V) | 60906 | 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C25H27N3O7S | 详情 | 详情 | |
(VI) | 60907 | N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-4'-formyl-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C25H28N2O8S | 详情 | 详情 | |
(VII) | 60908 | N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C25H30N2O8S | 详情 | 详情 | |
(VIII) | 60909 | 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C25H29BrN2O7S | 详情 | 详情 | |
(IX) | 15118 | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 1,3-Diazaspirol[4,4]non-1-en-4-one,2-butyl | 151257-01-1 | C11H18N2O | 详情 | 详情 |
(X) | 60910 | 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C36H46N4O8S | 详情 | 详情 | |
(XI) | 60911 | 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl[1,1'-biphenyl]-2-sulfonamide | C30H34N4O5S | 详情 | 详情 |
合成路线2
Alternatively, reduction of 4-bromo-3-formylbenzonitrile ethylene ketal (XII) by means of DIBAL leads to aldehyde (XIII), which is further reduced to alcohol (XIV) with NaBH4. After bromination of (XIV) with CBr4/PPh3, the resultant benzyl bromide (XV) is condensed with the spiro imidazolone (IX), yielding (XVI). Then, acidic ketal hydrolysis in (XVI) furnishes aldehyde (XVII). Suzuki coupling between aryl bromide (XVII) and boronic acid (XVIII) gives biphenyl (XIX). The SEM group of (XIX) is then removed under acidic conditions to provide (XI)
【1】 Murugesan, N.; Tellew, J.E.; Gu, Z.; et al.; Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem 2002, 45, 18, 3829. |
【2】 Macor, J.E.; Murugesan, N.; Gu, Z.; Tellew, J.E. (Bristol-Myers Squibb Co.); Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists. EP 1094816; JP 2002519380; US 2002143024; WO 0001389 . |
【3】 Macor, J.E.; Murugesan, N.; Gu, Z.; Tellew, J.E. (Bristol-Myers Squibb Co.); Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists. EP 1237888; WO 0144239 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(IX) | 15118 | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 1,3-Diazaspirol[4,4]non-1-en-4-one,2-butyl | 151257-01-1 | C11H18N2O | 详情 | 详情 |
(XI) | 60911 | 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl[1,1'-biphenyl]-2-sulfonamide | C30H34N4O5S | 详情 | 详情 | |
(XII) | 60912 | 4-bromo-3-(1,3-dioxolan-2-yl)benzonitrile | C10H8BrNO2 | 详情 | 详情 | |
(XIII) | 60913 | 4-bromo-3-(1,3-dioxolan-2-yl)benzaldehyde | C10H9BrO3 | 详情 | 详情 | |
(XIV) | 60914 | [4-bromo-3-(1,3-dioxolan-2-yl)phenyl]methanol | C10H11BrO3 | 详情 | 详情 | |
(XV) | 60915 | 2-[2-bromo-5-(bromomethyl)phenyl]-1,3-dioxolane | C10H10Br2O2 | 详情 | 详情 | |
(XVI) | 60916 | 3-[4-bromo-3-(1,3-dioxolan-2-yl)benzyl]-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one | C21H27BrN2O3 | 详情 | 详情 | |
(XVII) | 60917 | 2-bromo-5-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]benzaldehyde | C19H23BrN2O2 | 详情 | 详情 | |
(XVIII) | 60918 | 2-({(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino}sulfonyl)phenylboronic acid | C15H21BN2O7S | 详情 | 详情 | |
(XIX) | 60919 | 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide | C34H42N4O7S | 详情 | 详情 |
合成路线3
Reductive amination of the biphenyl aldehyde (XI) with 4-amino-2,2-dimethylbutanoic acid (XX) in the presence of NaBH(OAc)3 produces aminoacid (XXI). This is finally cyclized to the corresponding lactam by treatment with DIC
【1】 Murugesan, N.; Tellew, J.E.; Gu, Z.; et al.; Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem 2002, 45, 18, 3829. |
【2】 Macor, J.E.; Murugesan, N.; Gu, Z.; Tellew, J.E. (Bristol-Myers Squibb Co.); Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists. EP 1094816; JP 2002519380; US 2002143024; WO 0001389 . |
【3】 Macor, J.E.; Murugesan, N.; Gu, Z.; Tellew, J.E. (Bristol-Myers Squibb Co.); Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists. EP 1237888; WO 0144239 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(XI) | 60911 | 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl[1,1'-biphenyl]-2-sulfonamide | C30H34N4O5S | 详情 | 详情 | |
(XX) | 60920 | 4-amino-2,2-dimethylbutanoic acid | C6H13NO2 | 详情 | 详情 | |
(XXI) | 60921 | 4-{[(4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-{[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}[1,1'-biphenyl]-2-yl)methyl]amino}-2,2-dimethylbutanoic acid | C36H47N5O6S | 详情 | 详情 |